ReviewInternational journal of molecular sciences2023
Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Efficacy and safety of AAV RPGR gene therapy in X-linked retinitis pigmentosa: a systematic review and meta-analysis.Journal of translational medicine · 2026Pooled it
- A systematic review of neuroprotective therapies for visual acuity preservation in retinitis pigmentosa.BMJ open ophthalmology · 2026Pooled it
- Efficacy and safety of minocycline in retinitis pigmentosa: a prospective, open-label, single-arm trial.Signal transduction and targeted therapy · 2024Trial
- Phase I/IIa Study of an Intravitreal Optogenetic Therapy (AGN-151597) in Patients with Advanced Retinitis Pigmentosa.Ophthalmology science · 2026Article
- Machine Learning-Based Classification of Retinitis Pigmentosa from Color Fundus Images: A Reproducible Benchmark and Screening-Oriented Pipeline.Vision (Basel, Switzerland) · 2026Article
- The efficacy and safety of oral and topical carbonic anhydrase inhibitors for the treatment of macular edema secondary to retinitis pigmentosa: a systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Lateral Geniculate Nucleus Volume Assessment Using Linear Mixed Model in Moderate and Advanced Retinitis Pigmentosa.Journal of clinical medicine · 2026Article
- Past studies suggest potential therapies for newly discovered retinitis pigmentosa mutations in U6 and U4 snRNAs.RNA (New York, N.Y.) · 2026Article
- Lycium barbarum glycopeptide and luteolin synergistically protect mouse photoreceptors against N-nitroso-N-methylurea-induced degeneration.Neural regeneration research · 2026Article
- Causal Relationship Between Blood Proteome and Retinitis Pigmentosa: A Mendelian Randomization Study.Translational vision science & technology · 2026Article
- Generation of a human-induced pluripotent stem cell line from a retinitis pigmentosa patient carrying biallelic mutations in EYS gene.Human cell · 2026Article
- Interleukin 27-induced photoreceptor survival is associated with suppression of a novel Muller glia subpopulation.Cell communication and signaling : CCS · 2026Article
- Age-Stratified Genetic Spectrum of Retinitis Pigmentosa in Korean Patients: Predominance ofAnnals of laboratory medicine · 2026Article
- Living with Retinitis Pigmentosa in Türkiye: Diagnosis, Independence, and Access to Care.Healthcare (Basel, Switzerland) · 2026Article
- Article
- Capsular Tension Ring Implantation Improves Intraocular Lens Power Prediction Accuracy in Cataract with Retinitis Pigmentosa.Ophthalmology and therapy · 2026Article
- Test-retest variability of the full-field stimulus test in patients with retinitis pigmentosa: REPEAT Study Report No. 4.Acta ophthalmologica · 2026Article
- Targeting the CCL7-STAT1 axis attenuates microglial neurotoxicity and photoreceptor degeneration in retinitis pigmentosa.Journal of neuroinflammation · 2026Article
- Editorial: Retinitis pigmentosa, macular degeneration and related diseases.Frontiers in cellular neuroscience · 2026Article
- Detection of cystoid macular edema in patients with retinitis pigmentosa based on deep learning.International journal of retina and vitreous · 2025Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinitis pigmentosa (RP) comprises a group of inherited retinal dystrophies characterized by the degeneration of rod photoreceptors, followed by the degeneration of cone photoreceptors. As a result of photoreceptor degeneration, affected individuals experience gradual loss of visual function, with primary symptoms of progressive nyctalopia, constricted visual fields and, ultimately, central vision loss. The onset, severity and clinical course of RP shows great variability and unpredictability, with most patients already experiencing some degree of visual disability in childhood. While RP is currently untreatable for the majority of patients, significant efforts have been made in the development of genetic therapies, which offer new hope for treatment for patients affected by inherited retinal dystrophies. In this exciting era of emerging gene therapies, it remains imperative to continue supporting patients with RP using all available options to manage their condition. Patients with RP experience a wide variety of physical, mental and social-emotional difficulties during their lifetime, of which some require timely intervention. This review aims to familiarize readers with clinical management options that are currently available for patients with RP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.